# Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

> **NCT02689440** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 155 (actual)

## Conditions studied

- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Dasatinib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT02689440
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-02-19
- **Primary completion:** 2040-12-31
- **Final completion:** 2040-12-31
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02689440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02689440, "Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02689440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*